The efficacy of 308nm laser treatment of psoriasis compared to historical controls

Dermatology Online Journal

Volumn 7, Issue 2, 2001, Pages

  Rodewald, Erin J ^a   Housman, Tamara Salam ^a   Mellen, Beverly G ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; FLUOCINONIDE; INFLIXIMAB; PLACEBO; RETINOID DERIVATIVE; TAZAROTENE; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

BLISTER; BURN; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; KAPLAN MEIER METHOD; LOW LEVEL LASER THERAPY; MEDLINE; PHOTOTHERAPY; PRURITUS; PSORIASIS; PUBLICATION; RASH; REVIEW; SKIN EXFOLIATION; STANDARD; SYSTEMIC THERAPY; ULTRAVIOLET B RADIATION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; HOSPITALIZATION; LASER; META ANALYSIS; METHODOLOGY; RHEUMATOID ARTHRITIS; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DATABASES; DERMATOLOGIC AGENTS; HUMANS; LASERS; PHOTOTHERAPY; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 0035554011     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Feldman SR: Psoriasis Treatment. Curr Prob Dermatol 1998;10:1-40.
2. Clark AR, Feldman SR, Fleischer AB Jr: The safety and efficacy of phototherapy is similar in the elderly and non-elderly. J Geriatr Dermatol 1996;4:1-6.
3. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42(5 Pt 1):796-802. PubMed
4. Gottlieb AB: Product development for psoriasis: Clinical challenges and opportunities. 1998;3rd:421-433.
5. Asawanonda P, Anderson RR, Chang Y, Taylor CR. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000;136(5):619-24. PubMed
6. Feldman SR, Mellen BG, Salam TN, et al: Efficacy of 308 nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. In press.
7. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins;1996.
8. Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid. Dermatologica 1978;157(4):238-44. PubMed
9. Christophers E, Mrowietz U, Henneicke HH, Farber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992;26(1):86-90. PubMed
10. Hofer A, Fink-Puches R, Kerl H, Wolf P. Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol 1998;138(1):96-100. PubMed
11. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000;200(1):17-24. PubMed
12. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995;32(1):67-72. PubMed
13. Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI, Quell JM, Sefton J, Lue JC, Gibson JR, Chandraratna RA. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38(5 Pt 1):705-11. PubMed
14. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA, Lue JC, Sefton J, Gibson JR, Chandraratna RA. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37(1):85-92. PubMed
15. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989;20(6):1088-93. PubMed
16. Lauharanta J, Juvakoski T, Lassus A. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 1981;104(3):325-32. PubMed
17. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993;187 Suppl 1:8-18. PubMed
18. Timonen P, Friend D, Abeywickrama K, Laburte C, von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol 1990;122 Suppl 36:33-9. PubMed
19. Meffert H, Brautigam M, Farber L, Weidinger G. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997;77(2):137-41. PubMed
20. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130(3):366-75. PubMed
21. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32(1):78-88. PubMed
22. Van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988;118(2):183-90. PubMed
23. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90. PubMed
24. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842-7. PubMed
25. Bailit H, Federico J, McGivney W: Use of outcomes studies by a managed care organization: valuing measured treatment effects. Med Care 1995;33(suppl):AS216-AS225.
26. Sheingold SH: Can Bayesian methods make data and analyses more relevant to decision makers?: International Journal of Technology Assessment in Health Care 2001;17:114-122.
27. Zarkowsky H. Managed care organizations' assessment of reimbursement for new technology, procedures, and drugs. Arch Pathol Lab Med 1999;123(8):677-9. PubMed
28. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-91. PubMed